Scarica l'app Stockscreener
18.14
25.96%
-6.36
Precedente Chiudi:
$24.50
Aprire:
$24.66
Volume 24 ore:
6.62M
Relative Volume:
6.20
Capitalizzazione di mercato:
$567.60M
Reddito:
-
Utile/perdita netta:
$-69.47M
Rapporto P/E:
-3.2408
EPS:
-5.5973
Flusso di cassa netto:
$-73.92M
1 W Prestazione:
-32.11%
1M Prestazione:
-28.86%
6M Prestazione:
-38.67%
1 anno Prestazione:
-41.07%
Intervallo 1D:
$15.70
$24.79
Intervallo di 1 settimana:
$15.70
$27.84
Portata 52W:
$15.70
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Nome
Lenz Therapeutics Inc
Settore
Industria
Telefono
858-925-7000
Indirizzo
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Confronta LENZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
18.14 | 766.60M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2025-03-18 | Iniziato | TD Cowen | Buy |
| 2024-09-27 | Iniziato | Raymond James | Outperform |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-04-10 | Iniziato | Citigroup | Buy |
| 2024-03-27 | Iniziato | Piper Sandler | Overweight |
| 2023-02-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Downgrade | Cowen | Outperform → Market Perform |
| 2023-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-01-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-06 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-14 | Iniziato | BTIG Research | Buy |
| 2022-03-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Iniziato | Morgan Stanley | Overweight |
| 2021-07-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Lenz Therapeutics Inc Borsa (LENZ) Ultime notizie
LENZ Therapeutics (NASDAQ:LENZ) Sees Large Volume IncreaseShould You Buy? - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year LowShould You Sell? - MarketBeat
LENZ Therapeutics Responds to FDA Adverse Event Report - TipRanks
LENZ Therapeutics Addresses Adverse Event Report - TradingView — Track All Markets
Lenz plunges after adverse event report on eye therapy - MSN
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report - GuruFocus
LENZ plunges after adverse event report on eye therapy - Seeking Alpha
Stempoint Capital LP Buys Shares of 183,912 LENZ Therapeutics, Inc. $LENZ - MarketBeat
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
LENZ Therapeutics (LENZ) Receives a Buy from Citi - The Globe and Mail
Stock Analysis: Will LENZ Therapeutics Inc stock rally after Fed decisionsWeekly Investment Summary & Long-Term Safe Investment Ideas - BỘ NỘI VỤ
Saturn V Capital Management LP Invests $10.03 Million in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Will LENZ Therapeutics Inc. stock gain from strong economyJuly 2025 Highlights & Smart Swing Trading Alerts - Newser
Transcript : LENZ Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Lenz Therapeutics: A Close Look (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 6.1%Here's What Happened - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires New Stake in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Geode Capital Management LLC Grows Stock Position in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ - Ophthalmology Times
Leadership: Lenz Therapeutics CEO gives people autonomy and responsibility - MSN
Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea - marketscreener.com
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics and Lotus Pharmaceutical Submit New Drug Application for VIZZ in South Korea to Treat Presbyopia - Quiver Quantitative
LENZ Therapeutics (Nasdaq: LENZ) logs 2nd ex-US VIZZ filing, up to $125 million milestones - Stock Titan
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Piper Sandler 37th Annual Healthcare Conference - LENZ Therapeutics
LENZ Therapeutics (Nasdaq: LENZ) to webcast three December investor conferences - Stock Titan
LENZ Therapeutics (NASDAQ:LENZ) Insider Shawn Olsson Sells 10,000 Shares - MarketBeat
Building trade automation scripts for LENZ Therapeutics Inc.July 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Ranking LENZ Therapeutics Inc. among high performing stocks via toolsEarnings Recap Summary & Short-Term High Return Strategies - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock By Investing.com - Investing.com South Africa
How LENZ Therapeutics Inc. stock reacts to oil prices2025 Price Targets & High Return Stock Watch Alerts - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock - Investing.com
LENZ Therapeutics CCO Shawn Olsson Sells 10,000 Shares - TradingView
Officer Olsson Sells 10,000 ($261K) Of LENZ Therapeutics Inc [LENZ] - TradingView
Is LENZ Therapeutics Inc. stock a buy in volatile marketsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Signal strength of LENZ Therapeutics Inc. stock in tech scannersJuly 2025 Institutional & Weekly Stock Performance Updates - newser.com
How LENZ Therapeutics Inc. stock reacts to Fed rate cutsEarnings Risk Report & Technical Confirmation Alerts - newser.com
Is LENZ Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - newser.com
Combining price and volume data for LENZ Therapeutics Inc.Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Can LENZ Therapeutics Inc. stock maintain operating marginsRate Hike & Precise Swing Trade Entry Alerts - newser.com
Tools to assess LENZ Therapeutics Inc.’s risk profileWeekly Earnings Recap & Low Drawdown Trading Techniques - newser.com
Candriam S.C.A. Takes $5.02 Million Position in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz Therapeutics Inc Azioni (LENZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lenz Therapeutics Inc Azioni (LENZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):